Other Affiliated Sites
Simplified Chinese
Traditional Chinese
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
Global Industrial Chain
Global Heparin Injections Business
Product Profile
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Contact Us
Create Value for Investors Through
Safe and Stable Operations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Disclosures
A-Share Information
H-Share Information
A-Share Information
H-Share Information
2020.08.01
独立董事候选人声明
2020.08.01
第四届董事会第三十六次会议决议公告
2020.07.31
STABILIZING ACTIONS, END OF STABILIZATION PERIOD AND LAPSE OF THE OVER-ALLOTMENT...
2020.07.31
关于稳定价格行动、稳定价格期间结束及超额配售权失效的公告
2020.07.31
关于公司问询函中有关财务事项的说明
2020.07.31
关于公司问询函中有关财务事项的说明
2020.07.31
关于对深圳证券交易所2019年年报问询函回复的公告
2020.07.15
2020年半年度业绩预告
2020.07.14
INSIDE INFORMATION ANNOUNCEMENT REGARDING THE ESTIMATED RESULTS FOR THE FIRST HA...
2020.07.08
关于境外上市外资股（H股）挂牌并上市交易的公告
第一页
上一页
58
59
60
61
62
下一页
最后一页
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Contact Us
Official WeChat Account
Legal Statement
·
Environmental Disclosure
Copyright © 2024 Hepalink Group. All Rights Reserved.
